and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

The company amended and restated employment agreements for key executives, modifying severance provisions.

The filing pertains to amendments in equity and stock purchase plans, not a management change.

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Other Events. On December 2, 2025, Kura Oncology, Inc. (the “ Company ”) announced the first U.S. commercial sale of KOMZIFTI ™ (ziftomenib) has been completed. Under the Company’s collaboration and license agreement with Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. (together, “ Kyowa Kirin ”), this milestone triggers a $135 million payment from Kyowa Kirin to the Company, which the Company expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on…

Other Events. On November 13, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced that the U.S. Food and Drug Administration (“FDA”) has granted full approval of KOMZIFTI TM (ziftomenib) for adult patients with relapsed or refractory (“R/R”) acute myeloid leukemia (“AML”) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated…

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Other Events. On October 24, 2025, Kura Oncology, Inc. (the “ Company ”) announced receipt of a $30 million milestone payment under its Collaboration and License Agreement with Kyowa Kirin, Inc. and Kyowa Kirin Co., Ltd. (together,“ Kyowa Kirin ”) in connection with the dosing of the first patient in the KOMET-017 Phase 3 registrational trials of ziftomenib, a once-daily, investigational oral menin inhibitor. The Company and Kyowa Kirin announced the launch of the KOMET-017 trials on Septembe…

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Entry into a Material Definitive Agreement. On June 27, 2025, Kura Oncology, Inc. (the “ Company ”) and Kyowa Kirin, Inc. (“ Kyowa Kirin US ”) entered into a Co-Promotion and Medical Affairs Agreement (the “ Co-Promotion Agreement ”) to co-promote the Company’s product candidate, ziftomenib, a potent, selective oral menin inhibitor, for the treatment of patients with acute myeloid leukemia and other hematologic malignancies in the United States and perform medical affairs activities with resp…

Other Events. On June 12, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced positive updated clinical data from KOMET-007, a Phase 1a/1b trial of ziftomenib, a highly selective oral investigational menin inhibitor, in combination with standards of care, cytarabine/daunorubicin (“7+3”), in patients with newly diagnosed nucleophosmin 1-mutant (“NPM1-m”) and KMT2A-rearranged (“KMT2A-r”) acute myeloid leukemia (“AML”). In the ongoing study, ziftomenib d…

The filing pertains to an equity plan amendment and stockholder approval, not a management change.

Other Events. On June 1, 2025, Kura Oncology, Inc. (the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s New Drug Application (“NDA”) seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (“R/R”) acute myeloid leukemia (“AML”) with a nucleophosmin 1 (“NPM1”) mutation. The application has been granted Priority Review and assigned a Prescription Drug User Fee…

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Other Events. On February 5, 2025, Kura Oncology, Inc. (“Kura” or the “Company”) and Kyowa Kirin Co., Ltd. (“Kyowa Kirin”) announced positive topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly selective, once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (“R/R”) NPM1-mutant (“NPM1-m”) acute myeloid leukemia (“AML”). Topline data for KOMET-001 has been submitted for presentation at an upcoming medical conference i…

Entry into a Material Definitive Agreement. On January 13, 2025, Kura Oncology, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with HCP Life Science REIT, Inc. (“Landlord”) for the lease of approximately 32,512 square feet of rentable area of the building located at 4930 Directors Place, San Diego, California 92121 (the “Premises”). The commencement date of the Lease is expected to be the earlier to occur of (i) the date upon which the Company first commences to conduct bus…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

Chief Medical Officer — Stephen Dale, M.D.: Dr. Stephen Dale resigned to focus on personal health challenges.

Entry into a Material Definitive Agreement. On November 20, 2024, Kura Oncology, Inc. (the “ Company ”) and Kyowa Kirin Co., Ltd. and Kyowa Kirin, Inc. (together, “ Kyowa Kirin ”) entered into a collaboration and license agreement (the “ Agreement ”) to develop and commercialize globally the Company’s product candidate, ziftomenib, a potent, selective oral menin inhibitor, for the treatment of patients with acute myeloid leukemia (“ AML ”) and other hematologic malignancies. In addition, Kyow…

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.

Class III director and member of the Compensation Committee — Michael J. Vasconcelles, M.D.: Dr. Michael J. Vasconcelles was appointed as a Class III director and member of the Compensation Committee.

and Exhibit 99.1 hereto are being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.